Oramed Pharmaceuticals Inc
NASDAQ:ORMP

Watchlist Manager
Oramed Pharmaceuticals Inc Logo
Oramed Pharmaceuticals Inc
NASDAQ:ORMP
Watchlist
Price: 2.13 USD -0.93% Market Closed
Market Cap: 87m USD

Intrinsic Value

The intrinsic value of one ORMP stock under the Base Case scenario is 1.95 USD. Compared to the current market price of 2.13 USD, Oramed Pharmaceuticals Inc is Overvalued by 8%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ORMP Intrinsic Value
1.95 USD
Overvaluation 8%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Oramed Pharmaceuticals Inc

Valuation History Unavailable

Historical valuation for ORMP cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%
Compare ORMP to

Fundamental Analysis

Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ORMP?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Oramed Pharmaceuticals Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Oramed Pharmaceuticals Inc

Current Assets 131.5m
Cash & Short-Term Investments 130.6m
Other Current Assets 832k
Non-Current Assets 16.1m
Long-Term Investments 9.5m
PP&E 1m
Other Non-Current Assets 5.5m
Efficiency

Free Cash Flow Analysis
Oramed Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Oramed Pharmaceuticals Inc

Revenue
2m USD
Cost of Revenue
-2m USD
Gross Profit
13k USD
Operating Expenses
-14.3m USD
Operating Income
-14.3m USD
Other Expenses
-13.9m USD
Net Income
-28.2m USD
Fundamental Scores

ORMP Profitability Score
Profitability Due Diligence

Oramed Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Exceptional 1-Year Revenue Growth
ROIC is Increasing
ROE is Increasing
Negative 3-Years Revenue Growth
23/100
Profitability
Score

Oramed Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

ORMP Solvency Score
Solvency Due Diligence

Oramed Pharmaceuticals Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
69/100
Solvency
Score

Oramed Pharmaceuticals Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ORMP Price Targets Summary
Oramed Pharmaceuticals Inc

Wall Street analysts forecast ORMP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ORMP is 3.32 USD with a low forecast of 3.28 USD and a high forecast of 3.41 USD.

Lowest
Price Target
3.28 USD
54% Upside
Average
Price Target
3.32 USD
56% Upside
Highest
Price Target
3.41 USD
60% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Oramed Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ORMP is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ORMP Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one ORMP stock?

The intrinsic value of one ORMP stock under the Base Case scenario is 1.95 USD.

Is ORMP stock undervalued or overvalued?

Compared to the current market price of 2.13 USD, Oramed Pharmaceuticals Inc is Overvalued by 8%.

Back to Top